Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com
Key Trials Show Utility of Agents Across Therapeutic Classes in Gastric/GEJ Cancer
March 15th 2019Hope E. Uronis, MD, MHS, sheds light on therapeutic classes in gastric and esophageal cancer and the trials that have demonstrated their utility and refined their applicability across settings, subpopulations, and histologies of gastric/GEJ cancer.
Read More
Novel Therapeutics, Dosing Strategies Offer Hope in Metastatic Pancreatic Cancer
March 14th 2019Given the poor prognosis of pancreatic cancer and the steady stream of negative phase III trials, clinicians are facing an uphill battle in the treatment of patients with metastatic pancreatic cancer.
Read More
Bridging the Knowledge Gap Between Biosimilars and Biologics in Breast Cancer
March 11th 2019Since 2006, the European Medicines Agency has granted marketing authorization for more than 40 biosimilars, and, in less than 4 years, the FDA has approved 17, yet the knowledge gap in the understanding of biosimilarity poses a unique challenge to the agents’ assimilation into clinical practice and possible impact on access and cost savings, experts say.
Read More
Following Encouraging Therapeutic Advances, Focus in NETs Turns to Sequencing
March 6th 2019Ana Maria Cristina De Jesus-Acosta, MD, discusses somatostatin analogs and peptide receptor radionucleotide therapy, and spoke to the discussion regarding the optimal sequence of therapy in patients with neuroendocrine tumors.
Read More
CDK4/6 Inhibitors Carry Consistent Benefit Across HR+/HER2- Breast Cancer Settings
February 27th 2019Joseph F. Stilwill, MD, shares insight on the clinical benefit seen with CDK4/6 inhibitors in patients with advanced HR-positive, HER2-negative breast cancer and highlights ongoing research aimed at overcoming acquired resistance.
Read More
Neoadjuvant Pembrolizumab Regimen Active in TNBC
February 26th 2019The combination of the PD-1 inhibitor pembrolizumab and platinum/taxane chemotherapy in the neoadjuvant setting induced high rates of pathologic complete response in patients with locally advanced triple-negative breast cancer.
Read More
Consistent Findings Validate Viability of TKI Discontinuation in CML
February 14th 2019First- and second-generation TKIs confer a significant survival benefit for patients with chronic-phase chronic myeloid leukemia (CP-CML)—so much so, that treatment discontinuation has become a viable option for select patients.
Read More
Chao Discusses Impact of RAINBOW, TAGS, and KEYNOTE Trials in Gastric/GEJ Cancer
February 12th 2019The RAINBOW and TAGS trials have demonstrated strong evidence to support the use of ramucirumab and TAS-102 in patients with advanced gastric or gastroesophageal cancer who have progressed on first-line therapy.
Read More
CDK4/6 Inhibitors Changing Course of Care in HR+/HER2- Breast Cancer
February 9th 2019Earlier diagnosis and more effective therapeutic options are enabling physicians to deliver better rates of disease control and improved quality of life to patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Read More
Study Confirms Long-Term Risk of Secondary Cancers in Pediatric Hodgkin Lymphoma Survivors
February 7th 2019The relative risk of developing a solid subsequent malignant neoplasm remained elevated in survivors of childhood Hodgkin lymphoma, according to extended follow-up of more than 25 years from the Late Effects Study Group cohort.
Read More